Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30320123 | 0.83 | PARP1 (0.46) | CYP2C19ALOX5FFAR1PARP1KDM4E | |
| SCHEMBL198085 | 0.83 | PARP1 (0.46) | CYP2C19ALOX5FFAR1PARP1KDM4E | |
| SCHEMBL3798516 | 0.80 | ALOX5 (0.57) | ALOX5FFAR1PARP1KDM4EMAPT | |
| SCHEMBL3860960 | 0.80 | ALOX5 (0.42) | CYP2C19ALOX5FFAR1PARP1KDM4E | |
| SCHEMBL13990693 | 0.78 | PARP1 (0.51) | ALOX5FFAR1PARP1MAPTHSD17B10 | |
| SCHEMBL1401562 | 0.77 | PARP1 (0.46) | CYP2C19ALOX5FFAR1PARP1MAPT | |
| SCHEMBL27318901 | 0.74 | KDM4E (0.60) | ALOX5PARP1KDM4EMAPTHPGD | |
| SCHEMBL23071738 | 0.73 | CYP1A2 (0.57) | CYP1A2CYP2D6CYP2C19ALOX5KDM4E | |
| SCHEMBL20402334 | 0.72 | ALOX5 (0.55) | CYP1A2CYP2D6CYP2C19ALOX5KDM4E | |
| SCHEMBL12412363 | 0.71 | CYP1A2 (0.81) | CYP1A2CYP2D6CYP2C19KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585839-B2 | Cyclic and linear oligopeptides; capable of increasing gap junction conductance; lack the proarrhythmic side effects; use as drug to also treat eye disorders, cancer, and gastrointestinal disorders among others | ZEALAND PHARMA A/S (DK) | 2009-09-08 | — | — | US | disclosed |
| US-20070042964-A1 | Compositions and methods for modulating connexin hemichannels | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| US-7153822-B2 | Compositions and methods for modulating connexin hemichannels | WYETH (US) | 2006-12-26 | — | — | US | disclosed |
| US-20050113293-A1 | Medical uses of intercellular communication facilitating compounds | ZEALAND PHARMA A/S | 2005-05-26 | — | — | US | disclosed |
| EP-1469875-A1 | COMPOSITIONS AND METHODS FOR MODULATING CONNEXIN HEMICHANNELS | Wyeth (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040092429-A1 | Compositions and methods for modulating connexin hemichannels | ZEALAND PHARMA A/S | 2004-05-13 | — | — | US | disclosed |
| EP-1370276-A2 | MEDICAL USES OF INTERCELLULAR COMMUNICATION FACILITATING COMPOUNDS | Zealand Pharma A/S (DK) | 2003-12-17 | — | — | EP | disclosed |
| WO-2003063891-A1 | COMPOSITIONS AND METHODS FOR MODULATING CONNEXIN HEMICHANNELS | WYETH (US) | 2003-08-07 | — | — | WO | disclosed |
| WO-2002077017-A2 | MEDICAL USES OF INTERCELLULAR COMMUNICATION FACILITATING COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113293-A1 | Medical uses of intercellular communication facilitating compounds | GJB2, GJA1, TNNI3 | CYP1A2 4218/4885CYP2D6 2257/4885CYP2C19 2799/4885 |
| US-20070042964-A1 | Compositions and methods for modulating connexin hemichannels | GJB2, GJA1, HCN4 | CYP1A2 3316/4885CYP2D6 2453/4885CYP2C19 3754/4885 |
| US-20040092429-A1 | Compositions and methods for modulating connexin hemichannels | GJB2, GJA1, HCN4 | CYP1A2 3316/4885CYP2D6 2453/4885CYP2C19 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.